Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder.

Palis H, Marchand K, Karamouzian M, MacDonald S, Harrison S, Guh D, Lock K, Brissette S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Addict Behav Rep. 2018 Mar 27;7:82-89. doi: 10.1016/j.abrep.2018.03.005. eCollection 2018 Jun.

2.

A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder.

El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lespérance F, Lespérance P, Ouellet-Plamondon C, Bruneau J, Jutras-Aswad D.

Int Clin Psychopharmacol. 2018 Sep;33(5):268-273. doi: 10.1097/YIC.0000000000000223.

PMID:
29738425
3.

Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.

Bansback N, Guh D, Oviedo-Joekes E, Brissette S, Harrison S, Janmohamed A, Krausz M, MacDonald S, Marsh DC, Schechter MT, Anis AH.

Addiction. 2018 Jul;113(7):1264-1273. doi: 10.1111/add.14171. Epub 2018 Mar 28.

PMID:
29589873
4.

Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.

Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Rev. 2018 Jan;37(1):137-146. doi: 10.1111/dar.12573. Epub 2017 Jun 8.

PMID:
28593748
5.

Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.

Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Subst Abuse Treat Prev Policy. 2017 May 19;12(1):25. doi: 10.1186/s13011-017-0110-9.

6.

Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.

Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Depend. 2017 Jul 1;176:55-62. doi: 10.1016/j.drugalcdep.2017.02.021. Epub 2017 May 10.

PMID:
28521199
7.

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, Marsh DC, Schechter MT.

JAMA Psychiatry. 2016 May 1;73(5):447-55. doi: 10.1001/jamapsychiatry.2016.0109.

PMID:
27049826
8.

Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C.

Thibault A, Brissette S, Jutras-Aswad D.

Addict Sci Clin Pract. 2015 Feb 24;10:6. doi: 10.1186/s13722-015-0029-2. Review.

9.

[Opioid use disorder in patients with chronic non-cancer pain].

Brabant M, Brissette S, Lauzon P, Marsan S, Ouellet-Plamondon C, Pelletier MC.

Sante Ment Que. Fall 2014;39(2):117-32. French.

PMID:
25590547
10.

Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.

Oviedo-Joekes E, Sordo L, Guh D, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Addict Behav. 2015 Feb;41:81-6. doi: 10.1016/j.addbeh.2014.10.003. Epub 2014 Oct 7.

11.

A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trial.

Oviedo-Joekes E, Marchand K, Lock K, Chettiar J, Marsh DC, Brissette S, Anis AH, Schechter MT.

Addict Sci Clin Pract. 2014 Sep 29;9:21. doi: 10.1186/1940-0640-9-21.

12.

Estimating the size of the population of persons who inject drugs in the island of Montréal, Canada, using a six-source capture-recapture model.

Leclerc P, Vandal AC, Fall A, Bruneau J, Roy É, Brissette S, Archibald C, Arruda N, Morissette C.

Drug Alcohol Depend. 2014 Sep 1;142:174-80. doi: 10.1016/j.drugalcdep.2014.06.022. Epub 2014 Jun 24.

PMID:
25008106
13.

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.

Oviedo-Joekes E, Guh D, Marchand K, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Subst Abuse Treat Prev Policy. 2014 Jun 8;9:23. doi: 10.1186/1747-597X-9-23.

14.

A call for evidence-based medical treatment of opioid dependence in the United States and Canada.

Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, Wood E, Montaner JS.

Health Aff (Millwood). 2013 Aug;32(8):1462-9. doi: 10.1377/hlthaff.2012.0846.

15.

Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, Meikleham E, Schechter MT, Anis AH.

CMAJ. 2012 Apr 3;184(6):E317-28. doi: 10.1503/cmaj.110669. Epub 2012 Mar 12.

16.

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment.

Marchand K, Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Schechter MT.

Harm Reduct J. 2012 Jan 25;9:8. doi: 10.1186/1477-7517-9-8.

17.

Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.

Oviedo-Joekes E, Marsh DC, Guh D, Brissette S, Schechter MT.

J Opioid Manag. 2011 Sep-Oct;7(5):371-6.

PMID:
22165036
18.

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.

Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT.

BMC Health Serv Res. 2011 Jul 26;11:174. doi: 10.1186/1472-6963-11-174.

19.

Health related quality of life trajectories of patients in opioid substitution treatment.

Nosyk B, Guh DP, Sun H, Oviedo-Joekes E, Brissette S, Marsh DC, Schechter MT, Anis AH.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):259-64. doi: 10.1016/j.drugalcdep.2011.04.003. Epub 2011 May 4.

PMID:
21546173
20.

History of reported sexual or physical abuse among long-term heroin users and their response to substitution treatment.

Oviedo-Joekes E, Marchand K, Guh D, Marsh DC, Brissette S, Krausz M, Anis A, Schechter MT.

Addict Behav. 2011 Jan-Feb;36(1-2):55-60. doi: 10.1016/j.addbeh.2010.08.020. Epub 2010 Sep 19.

PMID:
20855171
21.

Characteristics and response to treatment among Aboriginal people receiving heroin-assisted treatment.

Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Nosyk B, Krausz M, Anis A, Christian WM, Spittal P, Schechter MT.

Can J Public Health. 2010 May-Jun;101(3):210-2.

PMID:
20737811
22.

Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women.

Oviedo-Joekes E, Guh D, Brissette S, Marchand K, Marsh D, Chettiar J, Nosyk B, Krausz M, Anis A, Schechter MT.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):50-7. doi: 10.1016/j.drugalcdep.2010.03.016. Epub 2010 May 26.

PMID:
20510551
23.

The effect of motivational status on treatment outcome in the North American Opiate Medication Initiative (NAOMI) study.

Nosyk B, Geller J, Guh DP, Oviedo-Joekes E, Brissette S, Marsh DC, Schechter MT, Anis AH.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):161-5. doi: 10.1016/j.drugalcdep.2010.03.019. Epub 2010 May 26.

PMID:
20510549
24.

Different roles, same goal: students learn about interprofessional practice in a clinical setting.

Takahashi S, Brissette S, Thorstad K.

Nurs Leadersh (Tor Ont). 2010 Mar;23(1):32-9.

PMID:
20383078
25.

Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.

Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, Anis A, Schechter MT.

J Subst Abuse Treat. 2010 Jun;38(4):408-11. doi: 10.1016/j.jsat.2010.03.003. Epub 2010 Mar 31.

PMID:
20359843
26.

The quality of eight health status measures were compared for chronic opioid dependence.

Nosyk B, Sun H, Guh DP, Oviedo-Joekes E, Marsh DC, Brissette S, Schechter MT, Anis AH.

J Clin Epidemiol. 2010 Oct;63(10):1132-44. doi: 10.1016/j.jclinepi.2009.12.003. Epub 2010 Mar 17.

PMID:
20236799
27.

Diacetylmorphine versus methadone for the treatment of opioid addiction.

Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT.

N Engl J Med. 2009 Aug 20;361(8):777-86. doi: 10.1056/NEJMoa0810635.

28.

Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study.

Oviedo-Joekes E, Nosyk B, Marsh DC, Guh D, Brissette S, Gartry C, Krausz M, Anis A, Schechter MT.

Clin Trials. 2009 Jun;6(3):261-71. doi: 10.1177/1740774509105222.

29.

The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment.

Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, Krausz M, Anis A, Schechter MT.

J Urban Health. 2008 Nov;85(6):812-25. doi: 10.1007/s11524-008-9312-9. Epub 2008 Aug 29.

30.
31.

Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users.

Monga N, Rehm J, Fischer B, Brissette S, Bruneau J, El-Guebaly N, Noël L, Tyndall M, Wild C, Leri F, Fallu JS, Bahl S.

Drug Alcohol Depend. 2007 Apr 17;88(1):1-8. Epub 2006 Oct 17.

PMID:
17049753
32.

Health and social services accessed by a cohort of Canadian illicit opioid users outside of treatment.

Noël L, Fischer B, Tyndall MW, Bradet DR, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Wild TC.

Can J Public Health. 2006 May-Jun;97(3):166-70.

PMID:
16827399
33.

Patterns of opioid and cocaine co-use: a descriptive study in a Canadian sample of untreated opioid-dependent individuals.

Leri F, Stewart J, Fischer B, Jürgen R, Marsh DC, Brissette S, Bruneau J, El-Guebaly N, Noël L, Tyndall MW, Wild TC.

Exp Clin Psychopharmacol. 2005 Nov;13(4):303-10.

PMID:
16366760
34.

Comorbid depression among untreated illicit opiate users: results from a multisite Canadian study.

Wild TC, el-Guebaly N, Fischer B, Brissette S, Brochu S, Bruneau J, Noël L, Rehm J, Tyndall M, Mun P.

Can J Psychiatry. 2005 Aug;50(9):512-8.

PMID:
16262105
35.

Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).

Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noël L, Tyndall M, Wild C, Mun P, Baliunas D.

J Urban Health. 2005 Jun;82(2):250-66. Epub 2005 May 4.

36.

Determinants of overdose incidents among illicit opioid users in 5 Canadian cities.

Fischer B, Brissette S, Brochu S, Bruneau J, el-Guebaly N, Noël L, Rehm J, Tyndall M, Wild C, Mun P, Haydon E, Baliunas D.

CMAJ. 2004 Aug 3;171(3):235-9.

37.

Medical prescription of heroin--a review.

Brissette S.

Can HIV AIDS Policy Law Rev. 2001;6(1-2):1, 92-8. English, French.

PMID:
11837010
38.

Reduced sensory and motor nerve conduction velocities in moderate drinkers.

D'Amour ML, Brissette S, Lavoie J, Butterworth RF.

Addict Biol. 2000 Jan 1;5(1):71-5. doi: 10.1080/13556210071298.

PMID:
20575821
39.
40.

Nursing care plan for adolescents and young adults with advanced cystic fibrosis.

Brissette S, Zinman R, Fielding M, Reidy M.

Issues Compr Pediatr Nurs. 1987;10(2):87-97. No abstract available.

PMID:
3650257
41.

Sexual activity and sleep in humans.

Brissette S, Montplaisir J, Godbout R, Lavoisier P.

Biol Psychiatry. 1985 Jul;20(7):758-63.

PMID:
4005334

Supplemental Content

Loading ...
Support Center